Abstract
Transcatheter closure of patent foramen ovale (PFO) is an effective strategy for preventing recurrence of paradoxical embolism. However, PFO closure is often associated with residual shunt, which is a risk of recurrent stroke. This study aimed to evaluate the relationship between the anatomical features of PFO and residual shunt. The degree of residual shunt and its relationship with the anatomical features of PFO were evaluated in 106 patients who underwent PFO closure at our institution between March 2011 and January 2022 and in whom contrast transthoracic echocardiography was performed 1 year later. The mean PFO tunnel length was 9.3 ± 3.6 mm and the mean PFO height was 3.2 ± 2.2 mm. Atrial septal aneurysm (ASA) was found in 37 patients. After PFO closure, residual shunt was observed in 28 patients (grade 1, n = 8; grade 2, n = 16; grade 3, n = 3; grade 4, n = 1). Univariate logistic analysis identified ASA to be associated with residual shunt (odds ratio 2.78, 95% confidence interval 1.14 to 6.79; p = 0.024). There was no association of residual shunt with the size of the PFO, the length of PFO tunnel, or the size of the device used for closure. Two of four patients with a large residual shunt of grade 3 or grade 4 were found to have device size mismatch. Residual shunt after PFO closure was observed in a quarter of patients and was related to the presence of ASA. A few patients had a large residual shunt due to the device size mismatch.
Graphical abstract
Similar content being viewed by others
Abbreviations
- ASA:
-
Atrial septal aneurysm
- PFO:
-
Patent foramen ovale
- RL:
-
Right to left
- TEE:
-
Transesophageal echocardiography
- TTE:
-
Transthoracic echocardiography
References
Diener HC, Hankey GJ. Primary and secondary prevention of ischemic stroke and cerebral hemorrhage: JACC focus seminar. J Am Coll Cardiol. 2020;75:1804–18.
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial—TOAST: trial of Org 10172 in acute stroke treatment. Stroke. 1993;24:35–41.
Lee PH, Song JK, Kim JS, Heo R, Lee S, Kim DH, et al. Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO trial. J Am Coll Cardiol. 2018;71:2335–42.
Nakayama R, Takaya Y, Akagi T, Watanabe N, Ikeda M, Nakagawa K, et al. Identification of high-risk patent foramen ovale associated with cryptogenic stroke: development of a scoring system. J Am Soc Echocardiogr. 2019;32:811–6.
Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Tirschwell DL, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377:1022–32.
Sondergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Thomassen L, et al. Patent foramen ovale closure or amtiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377:1033–42.
Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Chatellier G, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377:1011–21.
Deng W, Yin S, McMullin D, Inglessis-Azuaje I, Elmariah S, Hung J, et al. Residual shunt after patent foramen ovale closure and long-term stroke recurrence: a prospective cohort study. Ann Intern Med. 2020;172:3717–25.
Suligoj NC, Rojko M, Suligoj B, Zorc M, Kar S, Noc M. Long-term transesophageal echocardiography after patent foramen ovale closure by BioSTAR and Amplatzer patent foramen ovale occluders. Catheter Cardiovasc Interv. 2020;95:349–54.
Gevorgyan Fleming R, Kumar P, West B, Noureddin N, Rusheen J, Aboulhosn J, et al. Comparison of residual shunt rate and complications across 6 different closure devices for patent foramen ovale. Catheter Cardiovasc Interv. 2020;95:365–72.
Matsumura K, Gevorgyan R, Mangels D, Masoomi R, Mojadidi MK, Tobis J. Comparison of residual shunt rates in five devices used to treat patent foramen ovale. Catheter Cardiovasc Interv. 2014;84:455–63.
Greutmann M, Greutmann-Yantiri M, Kretschmar O, Senn O, Roffi M, Jenni R, et al. Percutaneous PFO closure with Amplatzer PFO occluder: predictors of residual shunts at 6 months follow-up. Congenit Heart Dis. 2009;4:252–7.
Moon J, Kim M, Oh PC, Shin DH, Park HM, Jo YY, et al. Residual shunt after patent foramen ovale device closure in patients with cryptogenic stroke: serial bubble contrast transesophageal echocardiography data. J Stroke Cerebrovasc Dis. 2019;28:347–53.
Sorensen SG, Aguilar H, McKnight WK, Thomas H, Muhlestein JB. Transcranial Doppler quantification of residual shunt after percutaneous patent foramen ovale closure. Comparison of two devices. J Interv Cardiol. 2010;23:575–80.
Marchese N, Pacilli MA, Inchingolo V, Fanelli R, Loperfido F, Vigna C. Residual shunt after percutaneous closure of patent foramen ovale with AMPLATZER occluder devices-influence of anatomic features: a transcranial Doppler and intracardiac echocardiography study. EuroIntervention. 2013;9:382–8.
Takaya Y, Nakayama R, Akagi T, Yokohama F, Miki T, Nakagawa K, et al. Importance of saline contrast transthoracic echocardiography for evaluating large right-to-left shunt in patent foramen ovale associated with cryptogenic stroke. Int J Cardiovasc Imaging. 2022;38:515–20.
Takaya Y, Watanabe N, Ikeda M, Akagi T, Nakayama R, Nakagawa K, et al. Importance of abdominal compression valsalva maneuver and microbubble grading in contrast transthoracic echocardiography for detecting patent foramen ovale. J Am Soc Echocardiogr. 2020;33:201–6.
Katsianos E, Oikonomou E, Kalogeras K, Manousaki A, Kalantzis C, Pantelidis P, et al. Residual right-to-left-shunt following transcatheter patent foramen ovale closure: the role of antithrombotic treatment. Curr Pharm Des. 2022;28:3305–12.
Susuri N, Obeid S, Ulmi M, Siontis GCM, Wahl A, Windecker S, et al. Second transcatheter closure for residual shunt following percutaneous closure of patent foramen ovale. EuroIntervention. 2017;13:858–66.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Nakayama, R., Takaya, Y., Akagi, T. et al. Relationship between patent foramen ovale anatomical features and residual shunt after patent foramen ovale closure. Cardiovasc Interv and Ther 39, 200–206 (2024). https://doi.org/10.1007/s12928-023-00979-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12928-023-00979-y